Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

San Diego Convention Center

Jun 16, 2024 7:00 AM - Jun 20, 2024 3:00 PM

111 W Harbor Drive, , San Diego, CA 92101 , USA

DIA 2024 Global Annual Meeting

Join us at the premier life sciences conference, celebrating our 60th anniversary! Discover 180+ sessions on Cell and Gene Therapy, Decentralized Clinical Trials, AI, ICH, and more. Get ready to tackle challenges, improve skills, network, and drive change for healthcare at DIA2024.

Supporting Regulatory Convergence and Reliance Through a Pharmaceutical Quality Knowledge Management Capability

Session Chair(s)

Theresa  Mullin, PhD

Theresa Mullin, PhD

Associate Center Director - Strategic Initiatives, CDER

FDA, United States

The session will provide an update on ICMRA's Pharmaceutical Quality Knowledge Management project, including an overview of learnings from the pilots on collaborative assessment of post-approval changes and hybrid inspections by multiple authorities.

Learning Objective : Describe the various workstreams of the ICMRA PQKM project, and their potential to support increased regulatory convergence and reliance with regards to product quality assessments and inspections; Summarise learnings arising from the ICMRA pilots on collaborative assessment of post-approval changes and hybrid inspections; Discuss potential for expansion and operationalization of the pilots.

Speaker(s)

Sean  Barry, PhD

Collaborative Assessment Pilot: Regulators’ Perspective

Sean Barry, PhD

Health Products Regulatory Authority (HPRA), Ireland

Senior Pharmaceutical Assessor

Sau L Lee, PhD

Collaborative Assessment Pilot: Regulators’ Perspective

Sau L Lee, PhD

FDA, United States

Deputy Super Office Director, OPQ, CDER

Stelios  Tsinontides, PhD, MA

Collaborative Hybrid Inspection Pilot (CHIP): Regulator's Perspective

Stelios Tsinontides, PhD, MA

FDA, United States

Office Director, OPMA, OPQ, CDER

Brendan  Cuddy, MSc

Collaborative Hybrid Inspection Pilot (CHIP): Regulator's Perspective

Brendan Cuddy, MSc

European Medicines Agency, Netherlands

Lead Scientific Officer

Susanne  Ausborn, PhD

Pilot Programs: Industry's Perspective

Susanne Ausborn, PhD

Roche, Switzerland

Global Head International Regulatory Policy

Srivdya  Srikant, MS

Pilot Programs: Industry's Perspectives

Srivdya Srikant, MS

Gilead Sciences, United States

Director, Global Regulatory Affairs- CMC

Evdokia  Korakianiti, PhD, MSc

Panel Discussion: Pilot Programs

Evdokia Korakianiti, PhD, MSc

European Medicines Agency, Netherlands

Head of Quality and Safety of Medicines

Yasuhiro  Kishioka, PhD

Panel Discussion: Pilot Programs

Yasuhiro Kishioka, PhD

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Reviewer Director, Office of Cellular and Tissue-based Products

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.